XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI can be given alone or in combination with androgen deprivation therapy Approval is based…

PARSONS, Kan., April 23, 2024 /PRNewswire/ — The Kansas Proving Grounds at Great Plains Industrial Park, a leading facility for testing and innovation, is proud to announce its partnership with SkyscoutAI Innovations Inc., a pioneer in AI-powered wildfire detection and response using…

NEW YORK, April 23, 2024 /PRNewswire/ — The global radiopharmaceuticals market size is estimated to grow by USD 4612.62 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of almost 10.22% during the forecast period. The prevalence of neurological…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.